IRIS
FORMISANO, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.005
EU - Europa 731
AS - Asia 190
AF - Africa 44
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.974
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 991
IT - Italia 502
CN - Cina 114
NL - Olanda 82
CI - Costa d'Avorio 43
IE - Irlanda 38
DE - Germania 32
IN - India 30
FI - Finlandia 22
FR - Francia 17
PK - Pakistan 16
VN - Vietnam 16
CA - Canada 12
SE - Svezia 11
GB - Regno Unito 9
BE - Belgio 5
IR - Iran 5
UA - Ucraina 4
GR - Grecia 3
HK - Hong Kong 3
AU - Australia 2
BZ - Belize 2
MY - Malesia 2
BD - Bangladesh 1
BG - Bulgaria 1
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
EU - Europa 1
JP - Giappone 1
PL - Polonia 1
RS - Serbia 1
RU - Federazione Russa 1
SG - Singapore 1
UZ - Uzbekistan 1
Totale 1.974
Salva come PNG Salva come JPEG
Città #
Chandler 204
Naples 143
Napoli 103
Ashburn 88
Amsterdam 82
Millbury 45
Beijing 38
Des Moines 37
Hicksville 32
Nanjing 28
Princeton 27
Lawrence 24
Boston 23
Pune 21
San Mateo 18
Dong Ket 16
Wilmington 15
Ottawa 11
Hebei 10
Houston 10
Lahore 10
Nanchang 10
Caserta 9
Seattle 9
Woodbridge 9
Formia 8
Modica 8
Redwood City 8
Casoria 7
Palma Campania 7
Angri 6
Council Bluffs 6
Tianjin 6
Milan 5
Rome 5
Salerno 5
San Giorgio a Cremano 5
Shenyang 5
Turin 5
Ardabil 4
Changsha 4
Fucecchio 4
Islamabad 4
Jiaxing 4
Leawood 4
Amalfi 3
Augusta 3
Casagiove 3
Castel San Giovanni 3
Fairfield 3
Hong Kong 3
Indiana 3
Jacksonville 3
Kronberg 3
Menlo Park 3
Mumbai 3
Nashville 3
Nürnberg 3
Pizzo 3
Salt Lake City 3
Belize City 2
Boardman 2
Brussels 2
Changchun 2
Dublin 2
Duncan 2
Edegem 2
Grumo Nevano 2
Harbin 2
Krefeld 2
Kuala Lumpur 2
La Canada Flintridge 2
Lomazzo 2
Luco dei Marsi 2
Monmouth Junction 2
Pozzuoli 2
Prato 2
Pátrai 2
Rawalpindi 2
San Marzano sul Sarno 2
Sydney 2
Villarosa 2
Battipaglia 1
Bergamo 1
Caivano 1
Cambridge 1
Casalnuovo 1
Chatsworth 1
Chicago 1
Chilliwack 1
Cologne 1
Falkenstein 1
Falls Church 1
Feni 1
Ferrara 1
Florence 1
Forlì 1
Frattamaggiore 1
Fremont 1
Genoa 1
Totale 1.239
Salva come PNG Salva come JPEG
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 84
Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer 61
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 60
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 56
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 55
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 53
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 50
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 49
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 46
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 46
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 44
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 42
Mechanisms of resistance to mTOR inhibitors 42
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 41
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 41
From biology to therapy: Improvements of therapeutic options in Lung cancer 41
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 41
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 40
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 39
Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated Kinase (ERK) paracrine signaling axis in basal-like breast cancer 38
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 38
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 37
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 37
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 37
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 36
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 36
Mechanisms of lapatinib resistance in HER2-driven breast cancer 35
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 35
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 33
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 30
A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ERþ/HER2 Metastatic Breast Cancer 30
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. 30
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 30
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors 29
Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor. 28
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 28
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 27
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 27
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 27
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 27
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 26
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 25
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 25
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors 25
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 24
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. 24
Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. 24
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. 24
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ERþ breast cancer 23
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 21
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 21
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 21
SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS 20
Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer 20
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 20
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 20
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 19
INHIBITION OF CANCER CELL GROWTH AND INVASION BY TARGETING C-SRC IN BREAST CANCER MODELS RESISTANT TO ANTI-HER2 DRUGS 19
Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population 19
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 19
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 18
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 16
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 15
The broad spectrum of cardiotoxicities from immunotherapies 14
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 14
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance 12
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer 11
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer 8
Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904) 7
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 5
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 5
Totale 2.170
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.184
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.184
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201913 0 0 0 0 0 0 0 0 0 10 0 3
2019/2020253 72 1 9 18 59 13 0 7 2 16 35 21
2020/2021191 3 0 6 1 17 14 13 6 31 27 44 29
2021/2022371 8 0 10 14 5 10 4 11 58 55 84 112
2022/2023628 63 38 31 28 69 76 15 58 88 92 42 28
2023/2024437 15 60 112 41 26 75 25 61 17 5 0 0
Totale 2.170